Torrent Pharmaceuticals Limited Earnings Summary — Q4 FY2026

• Revenue reached an all-time high of ₹4,197 Cr in Q4 FY2026, a 42% YoY growth.
• The balance sheet shows a massive spike in borrowings to ₹15,026 Cr, suggesting a major strategic acquisition.
• Net Profit significantly contracted to ₹364 Cr due to a massive jump in interest costs (₹236 Cr vs ₹56 Cr YoY).
• Depreciation more than doubled to ₹508 Cr, further impacting the bottom line following recent expansions.
• Operating margins (OPM) remain resilient at 32%, demonstrating strong core business pricing power.
• The company continues to pivot toward high-margin branded generics in India and Brazil.
• Interest coverage and debt servicing will be critical monitoring factors going forward.

Management is focused on integrating large acquisitions and transitioning toward a high-margin branded business in India and Brazil, which now contributes 74% of revenue.

Deteriorating

While top-line growth is explosive, the sudden surge in debt and interest costs has drastically compressed net profitability in the short term.

The outlook remains positive for top-line growth and operating efficiency, but net earnings will be under pressure until the new assets are fully integrated and debt is deleveraged.